DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Follow-Up Questions
Dbv Technologies SA 的 CEO 是谁？
Mr. Daniel Tasse 是 Dbv Technologies SA 的 Chief Executive Officer，自 2018 加入公司。
DBVTF 股票的价格表现如何？
DBVTF 的当前价格为 $0，在上个交易日 decreased 了 0%。
Dbv Technologies SA 的主要业务主题或行业是什么？
Dbv Technologies SA 属于 Biotechnology 行业，该板块是 Health Care
